May 12, 2026
Astellas Returns to Gene Therapy for Rare Disease XLMTM After Previous Trial Disaster
Five years after a disastrous trial where some boys died while others had astonishing recoveries, Astellas is returning with a revised gene therapy treatment for X-linked myotubular myopathy (XLMTM), offering new hope to a devastated rare disease community.
2 sources
00